Altimmune Balance Sheet Health
Financial Health criteria checks 6/6
Altimmune has a total shareholder equity of $194.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $210.6M and $16.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$197.82m |
Equity | US$194.10m |
Total liabilities | US$16.54m |
Total assets | US$210.64m |
Recent financial health updates
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
Feb 10Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?
Oct 11We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Jun 27Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth
Feb 12We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth
Oct 27Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Jun 27Recent updates
Buy Altimmune's Potential Market Disruption With Pemvidutide
Apr 12Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place
Mar 27Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally
Feb 27Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment
Feb 12Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
Feb 10Thoroughly Derisked, Altimmune Is Now A Great Buy
Jan 10Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?
Oct 11We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Jun 27Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth
Feb 12We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth
Oct 27Altimmune: Overreaction On NASH Data Creates Buying Opportunity
Sep 15Reassessing Altimmune
Sep 07Altimmune sets new 52-week high on rising volume
Aug 31Altimmune Q2 2022 Earnings Preview
Aug 10Altimmune: Several Catalysts In 2 Large Market Indications This Year
Jun 29Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Jun 27Altimmune's New Avatar As A Liver Disease Player
Apr 07Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Feb 01Altimmune: Changing Focus To Pemvidutide In 2022
Jan 03Altimmune: Changing The Thesis
Oct 16Here's Why Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Is The Least Of Shareholders Concerns
Sep 17We're Hopeful That Altimmune (NASDAQ:ALT) Will Use Its Cash Wisely
Aug 06Altimmune: NASH And Obesity At The End Of The COVID Tunnel
Jul 27Altimmune rises 5% on positive ALT-801 data in early-stage trial of overweight volunteers
Jun 16Altimmune gains 7% after AdCOVID shows strong immune response against COVID-19 variant in preclinical study
May 26Altimmune reports encouraging AdCOVID data in SARS-CoV-2 challenged mice
May 10We Think Altimmune (NASDAQ:ALT) Can Easily Afford To Drive Business Growth
May 02Investors Who Bought Altimmune (NASDAQ:ALT) Shares A Year Ago Are Now Up 459%
Mar 21Financial Position Analysis
Short Term Liabilities: ALT's short term assets ($209.6M) exceed its short term liabilities ($12.1M).
Long Term Liabilities: ALT's short term assets ($209.6M) exceed its long term liabilities ($4.4M).
Debt to Equity History and Analysis
Debt Level: ALT is debt free.
Reducing Debt: ALT has no debt compared to 5 years ago when its debt to equity ratio was 1.2%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALT has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 32.8% each year.